• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24117 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     National Institute for Health and Care Excellence (NICE) Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025     National Institute for Health and Care Excellence (NICE) Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025     National Institute for Health and Care Excellence (NICE) Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Prevention of hypersensitivity reactions to intravascular contrast media during medical imaging in adults]
2025     NIHR Health Services and Delivery Research programme Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025     HTA South [Vaporization with green laser for benign prostatic hyperplasia: a systematic review and assessment of medical, economic, ethical and organisational aspects]
2025     HTA South [Observation after mild head injury in patients on anticoagulation therapy: a systematic review and assessment of medical, economical and ethical aspects]
2025     Canary Health Service [Tumor treating fields (TTFields) therapy in people with newly diagnosed glioblastoma]
2025     Canary Health Service [FT-Raman spectroscopy with data analysis using machine learning for the diagnosis of platinum-resistant ovarian cancer]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (eosinophilic granulomatosis with polyangiitis) – 2nd Addendum to Project A24-113]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (eosinophilic granulomatosis with polyangiitis) – Addendum to Project A24-113]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma) – Addendum to Project A24-116]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Addendum to Project A24-110]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nemolizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nemolizumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (fibrosing interstitial lung diseases, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (systemic sclerosis associated interstitial lung disease, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipavibart (pre exposure prophylaxis of COVID 19) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pirtobrutinib (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabotegravir (HIV-1 infection in adolescents) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma, first line, combination with bortezomib, lenalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (diffuse large B-cell lymphoma [DLBCL]) – Addendum to Project A24-108]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (sickle cell disease) – Assessment according to §35a (para. 1, sentence 11) Social Code]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion dependent beta thalassaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy, 1 to 3 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CRP apheresis in acute anterior myocardial infarction Addendum to project E22-11]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Phonocardiography to rule out coronary heart disease (Addendum to Project E19-09)]
2025     Andalusian Health Technology Assessment Area (AETSA) [Impact of multidisciplinary hospital teams employing ultrasound-guided vascular access]
2025     NIHR Health Services and Delivery Research programme Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025     NIHR Health Technology Assessment programme Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025     NIHR Health Technology Assessment programme Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025     NIHR Health Services and Delivery Research programme Implementing routine assessment of perinatal anxiety: case studies
2025     NIHR Health Services and Delivery Research programme How to implement digital clinical consultations in UK maternity care: the ARM@DA Realist Review
2025     Health Information and Quality Authority (HIQA) Evidence review of specialist cardiac services
2025     Agency for Care Effectiveness (ACE) Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025     Agency for Care Effectiveness (ACE) Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025     Agency for Care Effectiveness (ACE) Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025     Agency for Care Effectiveness (ACE) Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025     NIHR Health Technology Assessment programme Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025     NIHR Health Technology Assessment programme Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025     NIHR Health Technology Assessment programme Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025     NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
2025     National Institute for Health and Care Excellence (NICE) Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025     National Institute for Health and Care Excellence (NICE) Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Algorithm for the management of low back pain with or without radicular pain]
2025     Agency for Care Effectiveness (ACE) Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025     Agency for Care Effectiveness (ACE) Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025     Agency for Care Effectiveness (ACE) Antibacterial envelope for implantable neurostimulator infection control
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025     NIHR Health Technology Assessment programme Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Non-pharmacological interventions, other than psychosocial ones, for youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Pharmacological treatment of migraine]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding vitamin-dependent rickets screening to neonatal screening]
2025     Technology Assessment at SickKids (TASK) A microcosting and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025     Agency for Care Effectiveness (ACE) EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025     Agency for Care Effectiveness (ACE) Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025     NIHR Health Technology Assessment programme High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs
2025     National Institute for Health and Care Excellence (NICE) Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour. NICE interventional procedures guidance 800
2025     National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2025     National Institute for Health and Care Excellence (NICE) Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. NICE technology appraisal guidance 1051
2025     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over. NICE technology appraisal guidance 1054
2025     National Institute for Health and Care Excellence (NICE) Cladribine for treating active relapsing forms of multiple sclerosis. NICE technology appraisal guidance 1053
2025     National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone for treating symptoms of endometriosis. NICE technology appraisal guidance 1057
2025     National Institute for Health and Care Excellence (NICE) Molnupiravir for treating COVID-19. NICE technology appraisal guidance 1056
2025     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1055
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025     NIHR Health and Social Care Delivery Program Opportunities and practices supporting responsive health care for forced migrants: lessons from transnational practice and a mixed-methods systematic review
2025     NIHR Health and Social Care Delivery Program Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: a realist review
2025     NIHR Health Technology Assessment programme A network approach to addressing the needs of patients with incurable head and neck cancer and their families
2025     NIHR Health and Social Care Delivery Program The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment
2025     Penn Medicine Center for Evidence-based Practice (CEP) Alpha-blocking medication before removal of indwelling urinary catheters
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Hospital at home in Québec healthcare institutions: considerations to support program implementation]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [New drug treatments for Alzheimer's disease: considerations for patient management]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of mitral insufficiency with a percutaneous device with clip (TEER) in Quebec - characteristics, continuum of care and clinical outcomes of adult clientele treated between 2019-2020 and 2021-2022]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of bladder cancer patients]
2025     NIHR Health and Social Care Delivery Program Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025     NIHR Health and Social Care Delivery Program Organising general practice for care homes: a multi-method study
2025     HTA South [Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025     NIHR Health and Social Care Delivery Program Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025     NIHR Health and Social Care Delivery Program Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025     NIHR Health Technology Assessment programme Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial